JP2016538854A5 - - Google Patents

Download PDF

Info

Publication number
JP2016538854A5
JP2016538854A5 JP2016532581A JP2016532581A JP2016538854A5 JP 2016538854 A5 JP2016538854 A5 JP 2016538854A5 JP 2016532581 A JP2016532581 A JP 2016532581A JP 2016532581 A JP2016532581 A JP 2016532581A JP 2016538854 A5 JP2016538854 A5 JP 2016538854A5
Authority
JP
Japan
Prior art keywords
car
nucleic acid
acid sequence
spacer
sequence encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016532581A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016538854A (ja
JP6433498B2 (ja
Filing date
Publication date
Priority claimed from GB201320573A external-priority patent/GB201320573D0/en
Priority claimed from GB201410934A external-priority patent/GB201410934D0/en
Application filed filed Critical
Priority claimed from PCT/GB2014/053453 external-priority patent/WO2015075470A1/en
Publication of JP2016538854A publication Critical patent/JP2016538854A/ja
Publication of JP2016538854A5 publication Critical patent/JP2016538854A5/ja
Application granted granted Critical
Publication of JP6433498B2 publication Critical patent/JP6433498B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016532581A 2013-11-21 2014-11-21 細胞 Active JP6433498B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1320573.7 2013-11-21
GB201320573A GB201320573D0 (en) 2013-11-21 2013-11-21 T Cell
GB201410934A GB201410934D0 (en) 2014-06-19 2014-06-19 T cell
GB1410934.2 2014-06-19
PCT/GB2014/053453 WO2015075470A1 (en) 2013-11-21 2014-11-21 Cell

Publications (3)

Publication Number Publication Date
JP2016538854A JP2016538854A (ja) 2016-12-15
JP2016538854A5 true JP2016538854A5 (cg-RX-API-DMAC7.html) 2018-08-02
JP6433498B2 JP6433498B2 (ja) 2018-12-05

Family

ID=52003983

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016532581A Active JP6433498B2 (ja) 2013-11-21 2014-11-21 細胞
JP2016532594A Active JP6538684B2 (ja) 2013-11-21 2014-11-21 細胞
JP2018240817A Withdrawn JP2019041775A (ja) 2013-11-21 2018-12-25 細胞
JP2020213272A Pending JP2021045172A (ja) 2013-11-21 2020-12-23 細胞

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016532594A Active JP6538684B2 (ja) 2013-11-21 2014-11-21 細胞
JP2018240817A Withdrawn JP2019041775A (ja) 2013-11-21 2018-12-25 細胞
JP2020213272A Pending JP2021045172A (ja) 2013-11-21 2020-12-23 細胞

Country Status (19)

Country Link
US (10) US20160296562A1 (cg-RX-API-DMAC7.html)
EP (6) EP3858378A1 (cg-RX-API-DMAC7.html)
JP (4) JP6433498B2 (cg-RX-API-DMAC7.html)
KR (2) KR101991555B1 (cg-RX-API-DMAC7.html)
CN (2) CN105848673B (cg-RX-API-DMAC7.html)
AU (2) AU2014351557B2 (cg-RX-API-DMAC7.html)
BR (2) BR112016011460A2 (cg-RX-API-DMAC7.html)
CA (2) CA2930215C (cg-RX-API-DMAC7.html)
CL (2) CL2016001134A1 (cg-RX-API-DMAC7.html)
DK (2) DK3071223T3 (cg-RX-API-DMAC7.html)
ES (2) ES2861501T3 (cg-RX-API-DMAC7.html)
HU (1) HUE051523T2 (cg-RX-API-DMAC7.html)
IL (2) IL245573B (cg-RX-API-DMAC7.html)
MX (2) MX377283B (cg-RX-API-DMAC7.html)
PL (2) PL3071222T3 (cg-RX-API-DMAC7.html)
PT (2) PT3071222T (cg-RX-API-DMAC7.html)
RU (2) RU2732236C2 (cg-RX-API-DMAC7.html)
SG (2) SG11201603484PA (cg-RX-API-DMAC7.html)
WO (3) WO2015075470A1 (cg-RX-API-DMAC7.html)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2795906C (en) 2009-04-13 2019-02-26 Inserm, Institut National De La Sante Et De La Recherche Medicale Hpv particles and uses thereof
EP2948544A4 (en) 2013-01-28 2016-08-03 St Jude Childrens Res Hospital CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES
CN120617536A (zh) 2013-09-18 2025-09-12 奥拉生物科学公司 用于诊断和治疗肿瘤的病毒样颗粒缀合物
GB201317928D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Molecule
MX377283B (es) 2013-11-21 2025-03-07 Ucl Business Ltd Célula t o nk que coexpresa un receptor antigénico quimérico (car).
JP6943568B2 (ja) 2013-12-06 2021-10-06 アメリカ合衆国 胸腺間質性リンパ球新生因子受容体特異的キメラ抗原受容体及びそれを使用する方法
PT3083671T (pt) 2013-12-20 2020-12-24 Hutchinson Fred Cancer Res Moléculas efetoras quiméricas etiquetadas e recetores destas
US20230027993A1 (en) 2014-03-05 2023-01-26 Autolus Limited Methods
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
GB201403972D0 (en) 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
KR102508166B1 (ko) 2014-04-10 2023-03-13 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 세포 면역요법을 위한 방법 및 조성물
AU2015259877B2 (en) 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
CA2954414A1 (en) 2014-07-15 2016-01-21 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
GB201415347D0 (en) * 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
JP2018504104A (ja) * 2014-12-17 2018-02-15 セレクティスCellectis 非T細胞伝達ドメインを発現する阻害性キメラ抗原受容体(iCARまたはN−CAR)
IL274903B (en) 2014-12-24 2022-07-01 Ucl Business Ltd A cell that simultaneously expresses a chimeric antigen receptor (car) of 19cd and 22cd
EP3250611B1 (en) * 2015-01-26 2021-04-21 The University of Chicago Car t-cells recognizing cancer-specific il 13r-alpha2
US20180002427A1 (en) 2015-01-26 2018-01-04 Cellectis Cll1-specific multi-chain chimeric antigen receptor
WO2016126213A1 (en) * 2015-02-06 2016-08-11 National University Of Singapore Methods for enhancing efficacy of therapeutic immune cells
CN114230670B (zh) * 2015-02-27 2025-06-03 美商生物细胞基因治疗有限公司 靶向血液恶性肿瘤之嵌合抗原受体(car)、其组合物及使用方法
HRP20220893T1 (hr) * 2015-04-08 2022-10-14 Novartis Ag Cd20 terapije, cd22 terapije, i kombinirane terapije sa stanicom koja eksprimira cd19 kimerni antigenski receptor
EP3286225B1 (en) * 2015-04-23 2020-07-01 Baylor College of Medicine Cd5 chimeric antigen receptor for adoptive t cell therapy
GB201507108D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
GB201507119D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507115D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507111D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
EP3288570A4 (en) * 2015-04-29 2018-11-21 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
GB201507368D0 (en) * 2015-04-30 2015-06-17 Ucl Business Plc Cell
ES2852973T3 (es) * 2015-05-15 2021-09-14 Hope City Composiciones de receptores de antígeno quimérico
CN108174607A (zh) * 2015-05-29 2018-06-15 朱诺治疗学股份有限公司 用于遗传工程改造的细胞中调节抑制性相互作用的组合物和方法
GB201509413D0 (en) * 2015-06-01 2015-07-15 Ucl Business Plc Fusion protein
CN107709552B (zh) * 2015-06-10 2022-05-13 南克维斯特公司 用于治疗癌症的修饰的nk-92细胞
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
JP6961497B2 (ja) 2015-06-25 2021-11-05 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体(CARs)の構成およびその使用方法
MA42895A (fr) * 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
GB201513540D0 (en) 2015-07-31 2015-09-16 King S College London Therapeutic agents
US11458167B2 (en) * 2015-08-07 2022-10-04 Seattle Children's Hospital Bispecific CAR T-cells for solid tumor targeting
GB201514874D0 (en) * 2015-08-20 2015-10-07 Autolus Ltd Cell
CN108348620A (zh) 2015-09-28 2018-07-31 明尼苏达大学董事会 嵌合抗原受体(car)t细胞作为获得自体免疫和同种免疫的治疗性干预
GB201518817D0 (en) * 2015-10-23 2015-12-09 Autolus Ltd Cell
BR112018008783A8 (pt) * 2015-10-30 2019-02-26 Aleta Biotherapeutics Inc terapia-alvo de câncer
GB201519900D0 (en) * 2015-11-11 2015-12-23 Ucl Business Plc Chimeric antigen receptor
AU2017225733A1 (en) * 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
US11400116B2 (en) 2016-05-06 2022-08-02 The Regents Of The University Of California Systems and methods for targeting cancer cells
EP3458077A4 (en) * 2016-05-17 2020-04-01 Chimera Bioengineering Inc. METHODS OF MANUFACTURING NEW AREAS OF ANTIGEN BINDING
JP7114490B2 (ja) 2016-06-24 2022-08-08 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体(CARs)の構成およびその使用方法
ES2981703T3 (es) * 2016-09-02 2024-10-10 Lentigen Tech Inc Composiciones y métodos para tratar cáncer con DuoCars
US20190359989A1 (en) * 2016-09-09 2019-11-28 Carsgen Therapeutics Co., Ltd. Fusion protein and applications thereof
US11219646B2 (en) * 2016-09-30 2022-01-11 Baylor College Of Medicine Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease
CA3039646A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer
WO2018087557A1 (en) 2016-11-11 2018-05-17 Autolus Limited Chimeric antigen receptor
JP7778468B2 (ja) 2016-11-22 2025-12-02 ナショナル ユニバーシティ オブ シンガポール T細胞悪性腫瘍の免疫療法のためのcd7発現およびキメラ抗原受容体の遮断
CN110291200B (zh) 2016-12-12 2024-05-14 西雅图儿童医院(Dba西雅图儿童研究所) 对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体
EP3568406A4 (en) * 2017-01-10 2020-10-21 The General Hospital Corporation T LYMPHOCYTES EXPRESSING A CHEMERICAL ANTIGENIC RECEPTOR
US20190375815A1 (en) * 2017-01-31 2019-12-12 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
RU2019128544A (ru) 2017-03-27 2021-04-28 Нэшнл Юниверсити Оф Сингапур Линии стимулирующих клеток для ex vivo размножения и активации клеток-натуральных киллеров
CN117384929A (zh) 2017-03-27 2024-01-12 新加坡国立大学 一种编码由细胞表达的嵌合受体的多核苷酸
KR20200005596A (ko) * 2017-05-12 2020-01-15 크리스퍼 테라퓨틱스 아게 세포를 엔지니어링하기 위한 물질 및 방법, 및 면역-종양학에서의 그의 용도
GB201707779D0 (en) 2017-05-15 2017-06-28 Autolus Ltd Cell
EP3634989A1 (en) * 2017-05-15 2020-04-15 Autolus Limited A cell comprising a chimeric antigen receptor (car)
GB201707783D0 (en) * 2017-05-15 2017-06-28 Autolus Ltd Cell
CA3070578A1 (en) 2017-06-21 2018-12-27 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars), compositions and methods thereof
CA3071495A1 (en) * 2017-08-02 2019-02-07 Autolus Limited Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
US20190038733A1 (en) 2017-08-10 2019-02-07 National University Of Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
EP3688155B1 (en) 2017-09-28 2023-01-04 Immpact-Bio Ltd. A universal platform for preparing an inhibitory chimeric antigen receptor (icar)
AU2018347601B2 (en) * 2017-10-12 2025-09-04 Icell Gene Therapeutics, Llc Compound chimeric antigen receptor (cCAR) targeting multiple antigens, compositions and methods of use thereof
GB201717524D0 (en) 2017-10-25 2017-12-06 Autolus Ltd Vectors
EP3700582A4 (en) 2017-10-25 2021-08-04 Actinium Pharmaceuticals, Inc. ANTI-CD45 LYMPHODELETION PROCESSES AND ASSOCIATED USES IN COMBINATION WITH ACT-BASED ANTI-CANCER THERAPIES
PL3703750T3 (pl) 2017-11-01 2025-04-07 Juno Therapeutics, Inc. Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy
AU2019219454A1 (en) 2018-02-09 2020-08-27 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
GB201803079D0 (en) * 2018-02-26 2018-04-11 Autolus Ltd Cell
CN112004829A (zh) 2018-03-12 2020-11-27 南克维斯特公司 Cd33car修饰的高亲和力nk细胞(t-hank)用于降低髓系衍生的抑制细胞的抑制活性(或降低对nk细胞活性的负面影响)的用途
JP7334985B2 (ja) 2018-04-02 2023-08-29 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
EP3790629A1 (en) 2018-05-11 2021-03-17 CRISPR Therapeutics AG Methods and compositions for treating cancer
EP3794034A1 (en) 2018-05-15 2021-03-24 Autolus Limited Chimeric antigen receptor
GB201807870D0 (en) 2018-05-15 2018-06-27 Autolus Ltd A CD79-specific chimeric antigen receptor
US12129485B2 (en) 2018-05-23 2024-10-29 National University Of Singapore Blockade of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignancies
CN110615842B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种包含共刺激受体的嵌合抗原受体及应用
GB201813178D0 (en) 2018-08-13 2018-09-26 Autolus Ltd Cell
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
CA3113896A1 (en) 2018-09-27 2020-04-02 Autolus Limited Chimeric antigen receptor
CN113164576A (zh) * 2018-10-05 2021-07-23 圣安娜儿童癌症研究中心 嵌合抗原受体(car)组
EP3632461A1 (en) * 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
WO2020070289A1 (en) 2018-10-05 2020-04-09 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
EP3632460A1 (en) * 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
GB201816522D0 (en) 2018-10-10 2018-11-28 Autolus Ltd Methods and reagents for analysing nucleic acids from single cells
SG11202104188VA (en) 2018-11-01 2021-05-28 Juno Therapeutics Inc Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
MX2021006968A (es) 2018-12-12 2021-10-13 Kite Pharma Inc Antígeno quimérico y receptores de las células t, y métodos de uso.
US20220133791A1 (en) 2019-01-23 2022-05-05 Miltenyi Biotec B.V. & Co. KG A Combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY
US20220145325A1 (en) 2019-03-08 2022-05-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
GB201903237D0 (en) 2019-03-08 2019-04-24 Autolus Ltd Method
TW202110873A (zh) 2019-04-30 2021-03-16 美商聖堤生物科技股份有限公司 嵌合受體及其使用方法
AU2020264484A1 (en) 2019-05-01 2021-11-04 Adoc Ssf, Llc Compositions and methods for the treatment of cancer using a CDB engineered T cell therapy
JP2022533128A (ja) * 2019-05-16 2022-07-21 ユニバーシティ オブ ワシントン Car t細胞のlockr媒介性動員
GB201909144D0 (en) 2019-06-25 2019-08-07 Autolus Ltd Culture medium
GB201910185D0 (en) 2019-07-16 2019-08-28 Autolus Ltd Method
WO2021009510A1 (en) 2019-07-16 2021-01-21 Autolus Limited Method for preconditioning a subject who is about to receive a t-cell therapy
EP4017510A4 (en) * 2019-08-20 2023-11-22 Senti Biosciences, Inc. CHIMERIC INHIBITOR RECEPTOR
EP4025594A2 (en) * 2019-09-05 2022-07-13 Migal Galilee Research Institute Ltd. Blocking chimeric antigen receptors for prevention of undesired activation of effector and regulatory immune cells
EP4031583A4 (en) * 2019-09-16 2023-11-15 Fred Hutchinson Cancer Center CHIMERIC RECEPTOR PROTEINS AND THEIR USES
EP4041893A4 (en) * 2019-10-08 2023-08-30 Provincial Health Services Authority CHEMERACY CYTOKINE RECEPTORS
WO2021108613A1 (en) 2019-11-26 2021-06-03 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
WO2021108670A1 (en) * 2019-11-26 2021-06-03 University Of Utah Research Foundation Compositions and methods for upregulating hla class i on tumor cells
MX2022006962A (es) 2019-12-11 2022-09-12 A2 Biotherapeutics Inc Receptor quimerico de antigenos basado en el miembro 1 de la subfamilia b de receptores similares a inmunoglobulina de leucocitos (lilrb1).
WO2021156277A1 (en) 2020-02-04 2021-08-12 Miltenyi Biotec B.V. & Co. KG Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens
EP4107174A4 (en) * 2020-02-20 2024-10-30 Senti Biosciences, Inc. ARCHITECTURES OF INHIBITORY CHIMERIC RECEPTORS
JP2023515055A (ja) * 2020-02-20 2023-04-12 センティ バイオサイエンシズ インコーポレイテッド 阻害性キメラ受容体アーキテクチャ
GB202007044D0 (en) 2020-05-13 2020-06-24 Autolus Ltd Method
US12286465B2 (en) 2020-05-28 2025-04-29 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains
GB202008957D0 (en) 2020-06-12 2020-07-29 Autolus Ltd Culture medium
US20230310606A1 (en) 2020-07-17 2023-10-05 Simurx, Inc. Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
MX2023002041A (es) * 2020-08-20 2023-04-27 A2 Biotherapeutics Inc Composiciones y métodos para tratar cánceres positivos para mesotelina.
CN116724052A (zh) 2020-08-20 2023-09-08 A2生物治疗股份有限公司 用于治疗ceacam阳性癌症的组合物和方法
RS65802B1 (sr) 2020-08-20 2024-08-30 A2 Biotherapeutics Inc Kompozicije i postupci za lečenje egfr pozitivnih kancera
US12215134B2 (en) * 2020-09-21 2025-02-04 A2 Biotherapeutics, Inc. Engineered immune cells with dominant signals
EP4228672A4 (en) * 2020-10-15 2024-12-18 Board of Trustees of the Leland Stanford Junior University COMPOSITIONS AND METHODS FOR INHIBITING NATURAL KILLER CELL RECEPTOR
WO2022096664A1 (en) 2020-11-09 2022-05-12 Miltenyi Biotec B.V. & Co. KG Methods and compositions for eliminating engineered immune cells
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス,インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
IL304857A (en) 2021-02-16 2023-10-01 A2 Biotherapeutics Inc Preparations and methods for treating HER2 POSITIVE cancer
US12144827B2 (en) 2021-02-25 2024-11-19 Lyell Immunopharma, Inc. ROR1 targeting chimeric antigen receptor
JP2024520430A (ja) * 2021-05-26 2024-05-24 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 阻害性キメラ抗原受容体は養子細胞治療のオンターゲット・オフ腫瘍効果を防止する
US20240336903A1 (en) * 2021-08-19 2024-10-10 Shandong Boan Biotechnology Co., Ltd. Fusion Proteins for Dephosphorylating Proteins that Regulate T Cell Activation through the TCR Signaling Pathway
GB202112923D0 (en) 2021-09-10 2021-10-27 Ucl Business Ltd Binding domain
WO2023057285A1 (en) 2021-10-06 2023-04-13 Miltenyi Biotec B.V. & Co. KG Method for targeted gene insertion into immune cells
WO2023218381A1 (en) 2022-05-11 2023-11-16 Autolus Limited Cd19/22 car t-cell treatment of high risk or relapsed pediatric acute lymphoblastic leukemia
GB202209920D0 (en) 2022-07-06 2022-08-17 Autolus Ltd Cell
WO2024078995A1 (en) 2022-10-15 2024-04-18 Miltenyi Biotec B.V. & Co. KG Transduction of gammadelta t cells with pseudotyped retroviral vectors
EP4520346A1 (en) 2023-09-06 2025-03-12 Gyncentrum Sp. z o.o. Cells, methods and systems for use in the treatment of a cancer with dual-car-t
GB202403564D0 (en) 2024-03-12 2024-04-24 Autolus Ltd Method
NL2037811B1 (en) 2024-05-29 2025-12-12 Univ Oslo Treatment for Cancer
WO2025259108A1 (en) 2024-06-11 2025-12-18 Prinses Máxima Centrum Voor Kinderoncologie B.V. Brain organoid

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9908807D0 (en) 1999-04-16 1999-06-09 Celltech Therapeutics Ltd Synthetic signalling molecules
EP1171596A1 (en) 1999-04-16 2002-01-16 Celltech Therapeutics Limited Synthetic transmembrane components
EP1334188B1 (en) * 2000-11-07 2006-08-30 City of Hope Cd19-specific redirected immune cells
MXPA04005010A (es) * 2001-11-26 2005-04-08 Advanced Cell Tech Inc METODO PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS METODOS PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS HUMANOS REPROGRAMADOS Y CELULAS DEL TALLO HUMANAS AUTOLOGAS E ISOGENICAS.
US9206440B2 (en) * 2009-01-23 2015-12-08 Roger Williams Hospital Viral vectors encoding multiple highly homologus non-viral polypeptides and the use of same
NO3012268T3 (cg-RX-API-DMAC7.html) * 2010-09-08 2018-04-14
JP6850528B2 (ja) * 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
BR112015023679A2 (pt) 2013-03-15 2017-10-24 Memorial Sloan Kettering Cancer Center composições e métodos para imunoterapia
MX377283B (es) 2013-11-21 2025-03-07 Ucl Business Ltd Célula t o nk que coexpresa un receptor antigénico quimérico (car).
KR102508166B1 (ko) * 2014-04-10 2023-03-13 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 세포 면역요법을 위한 방법 및 조성물
GB201507115D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507119D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201518817D0 (en) 2015-10-23 2015-12-09 Autolus Ltd Cell

Similar Documents

Publication Publication Date Title
JP2016538854A5 (cg-RX-API-DMAC7.html)
JP2016538855A5 (cg-RX-API-DMAC7.html)
RU2016124278A (ru) Клетка
JP2018523484A5 (cg-RX-API-DMAC7.html)
JP2017526361A5 (cg-RX-API-DMAC7.html)
JP6606210B2 (ja) Mndプロモーターのキメラ抗原受容体
JP2018517410A5 (cg-RX-API-DMAC7.html)
KR102523934B1 (ko) Bcma 키메릭 항원 수용체
JP7560356B2 (ja) 急性骨髄性白血病を治療するためのflt3 car-t細胞及びflt3阻害剤の使用
KR20240063204A (ko) Bcma 관련 암 및 자가면역 장애의 치료를 위한 조합 요법
JP7388798B2 (ja) Suv39h1を欠損する免疫細胞
JP2015518479A5 (cg-RX-API-DMAC7.html)
JP2018501794A5 (cg-RX-API-DMAC7.html)
JP2017537627A5 (cg-RX-API-DMAC7.html)
JP2019535292A5 (cg-RX-API-DMAC7.html)
BR112019018288A2 (pt) Métodos e composições para transduzir e expandir linfócitos e regular a atividade dos mesmos
CN111107866A (zh) 用于免疫疗法的pde5组合物和方法
RU2017105515A (ru) Сигнальная система
WO2018009923A1 (en) Methods and compositions for transducing lymphocytes and regulating the activity thereof
JP6416117B2 (ja) Jagged1に結合する抗体
JP2017518052A (ja) 改善されたt細胞組成物
KR20210149228A (ko) 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
WO2022006451A2 (en) Compositions and methods for tcr reprogramming using fusion proteins and pd-1 antibodies
CN112154204A (zh) 基因工程化的细胞及应用
KR20220042056A (ko) 골수성 세포 염증성 표현형을 조절하기 위한 항-siglec-9 조성물 및 방법, 그리고 이의 용도